Tabula Rasa HealthCare (NASDAQ:TRHC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “

TRHC has been the subject of a number of other research reports. BidaskClub upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research report on Wednesday, November 28th. Piper Jaffray Companies restated an “overweight” rating and set a $80.00 price objective on shares of Tabula Rasa HealthCare in a research report on Thursday. Chardan Capital raised their price objective on Tabula Rasa HealthCare from $77.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, November 7th. Cantor Fitzgerald restated a “buy” rating and set a $99.00 price objective on shares of Tabula Rasa HealthCare in a research report on Tuesday, November 6th. Finally, Citigroup raised their price objective on Tabula Rasa HealthCare from $57.00 to $76.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Tabula Rasa HealthCare has a consensus rating of “Buy” and a consensus target price of $82.50.

TRHC stock traded down $0.37 during trading on Thursday, reaching $72.01. The company’s stock had a trading volume of 19,594 shares, compared to its average volume of 276,240. Tabula Rasa HealthCare has a 1 year low of $27.25 and a 1 year high of $91.16. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.46 and a current ratio of 0.49. The firm has a market capitalization of $1.48 billion, a PE ratio of -1,800.25, a PEG ratio of 6.84 and a beta of 2.53.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Tuesday, November 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.07. Tabula Rasa HealthCare had a positive return on equity of 7.63% and a negative net margin of 13.49%. The business had revenue of $54.42 million during the quarter, compared to analyst estimates of $52.87 million. During the same quarter in the prior year, the business posted $0.08 EPS. Tabula Rasa HealthCare’s revenue for the quarter was up 66.3% compared to the same quarter last year. On average, sell-side analysts forecast that Tabula Rasa HealthCare will post 0.42 EPS for the current fiscal year.

In related news, CEO Calvin H. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $85.98, for a total value of $687,840.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gordon Tunstall sold 10,000 shares of Tabula Rasa HealthCare stock in a transaction dated Wednesday, November 28th. The stock was sold at an average price of $70.52, for a total value of $705,200.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 58,000 shares of company stock valued at $4,343,760. Company insiders own 14.00% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mount Yale Investment Advisors LLC bought a new stake in Tabula Rasa HealthCare in the second quarter worth about $111,000. Meadow Creek Investment Management LLC bought a new position in shares of Tabula Rasa HealthCare during the second quarter worth about $115,000. Envestnet Asset Management Inc. bought a new position in shares of Tabula Rasa HealthCare during the second quarter worth about $130,000. Pinebridge Investments L.P. bought a new position in shares of Tabula Rasa HealthCare during the second quarter worth about $181,000. Finally, Piedmont Investment Advisors LLC bought a new position in shares of Tabula Rasa HealthCare during the second quarter worth about $206,000. Institutional investors own 74.88% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

Featured Article: Swap

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.